ACADIA Pharmaceuticals(DE:DR6)
€16.24+0.58 (+3.70%)
DE:DR6
ACADIA Pharmaceuticals stock forecast
€16.24
At close:+0.58 (+3.70%)
ACADIA Pharmaceuticals (DR6) Stock Forecast & Price Target
0 Followers
DR6 Analyst Ratings
Strong Buy
11Buy3Hold0Sell
Based on 14 analysts giving stock ratings to ACADIA Pharmaceuticals in the past 3 months
DR6 Stock 12 Month Forecast
Average Price Target
€28.41▲(74.93% Upside)Based on 14 Wall Street analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is EUR 28.41 with a high forecast of EUR 34.35 and a low forecast of EUR 20.79. The average price target represents a 74.93% change from the last price of EUR 16.24.
Past 12 Months12 Month ForecastJan2026Oct2026
High€34.35
Average€28.41
Low€20.79
Highest Price TargetHighest€34.35Average Price Target€28.41Lowest Price TargetLowest€20.79
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Sean Laaman | Morgan Stanley | €25.31→€21.69 | hold | 33.59%Upside | Reiterated | 11/13/26 | ||
| Tazeen Ahmad | Bank of America Securities | €28.02 | buy | 72.55%Upside | Reiterated | 11/10/26 | ||
| Malcolm Hoffman | BMO Capital | €30.73 | buy | 89.25%Upside | Reiterated | 11/09/26 | ||
| Sumant Kulkarni | Canaccord Genuity | €32.54→€34.35 | buy | 111.51%Upside | Reiterated | 11/06/26 | ||
| Brian Abrahams | RBC Capital | €32.54→€34.35 | buy | 111.51%Upside | Assigned | 11/05/26 | ||
| Matthew Hershenhorn | Oppenheimer | €20.79 | hold | 28.02%Upside | Reiterated | 11/05/26 | ||
| Ritu Baral | TD Cowen | €33.45 | buy | 105.94%Upside | Reiterated | 11/05/26 | ||
 Unknown AnalystNot Ranked | Leerink Partners | €24.41 | buy | 50.28%Upside | Reiterated | 11/05/26 | ||
| Ami Fadia | Needham | €31.64 | buy | 94.81%Upside | Reiterated | 10/19/26 | ||
| Ashwani Verma | UBS | €44.29→€20.79 | hold | 28.02%Upside | Downgraded | 10/13/26 | ||
| Yigal Nochomovitz | Citi | €36.16→€29.83 | buy | 83.68%Upside | Reiterated | 09/25/26 | ||
| Jason Butler | Citizens JMP | €32.54→€29.83 | buy | 83.68%Upside | Reiterated | 09/25/26 | ||
| David Hoang | Deutsche Bank | €34.35→€28.02 | buy | 72.55%Upside | Reiterated | 09/25/26 | ||
| Ananda Ghosh | H.C. Wainwright | €33.45→€29.83 | buy | 83.68%Upside | Reiterated | 09/25/26 | ||
| Paul Matteis | Stifel Nicolaus | €22.60 | hold | 39.15%Upside | Reiterated | 08/05/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Sean LaamanMorgan Stanley | HoldReiterated€25.31→€21.69 | 11/13/26 | 33.59%Upside | ||
| Tazeen AhmadBank of America Securities | BuyReiterated€28.02 | 11/10/26 | 72.55%Upside | ||
| Malcolm HoffmanBMO Capital | BuyReiterated€30.73 | 11/09/26 | 89.25%Upside | ||
| Sumant KulkarniCanaccord Genuity | BuyReiterated€32.54→€34.35 | 11/06/26 | 111.51%Upside | ||
| Brian AbrahamsRBC Capital | BuyAssigned€32.54→€34.35 | 11/05/26 | 111.51%Upside | ||
| Matthew HershenhornOppenheimer | HoldReiterated€20.79 | 11/05/26 | 28.02%Upside | ||
| Ritu BaralTD Cowen | BuyReiterated€33.45 | 11/05/26 | 105.94%Upside | ||
| Unknown AnalystLeerink PartnersNot Ranked | BuyReiterated€24.41 | 11/05/26 | 50.28%Upside | ||
| Ami FadiaNeedham | BuyReiterated€31.64 | 10/19/26 | 94.81%Upside | ||
| Ashwani VermaUBS | HoldDowngraded€44.29→€20.79 | 10/13/26 | 28.02%Upside | ||
| Yigal NochomovitzCiti | BuyReiterated€36.16→€29.83 | 09/25/26 | 83.68%Upside | ||
| Jason ButlerCitizens JMP | BuyReiterated€32.54→€29.83 | 09/25/26 | 83.68%Upside | ||
| David HoangDeutsche Bank | BuyReiterated€34.35→€28.02 | 09/25/26 | 72.55%Upside | ||
| Ananda GhoshH.C. Wainwright | BuyReiterated€33.45→€29.83 | 09/25/26 | 83.68%Upside | ||
| Paul MatteisStifel Nicolaus | HoldReiterated€22.60 | 08/05/26 | 39.15%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering ACADIA Pharmaceuticals
3 Months
Success Rate9/13 ratings generated profit
69%
Average Return
+8.76%
Copying Tessa Romero's trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +8.76% per trade.
1 Year
Success Rate16/29 ratings generated profit
55%
Average Return
+6.59%
Copying Jason Butler's trades and holding each position for 1 Year would result in 55.17% of your transactions generating a profit, with an average return of +6.59% per trade.
2 Years
Success Rate8/20 ratings generated profit
40%
Average Return
+0.84%
Copying Ami Fadia's trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of +0.84% per trade.
DR6 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 6 | 1 | 7 | 12 | 17 |
| Buy | 16 | 29 | 26 | 20 | 5 |
| Hold | 6 | 9 | 9 | 8 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 28 | 39 | 42 | 40 | 27 |
In the current month, DR6 has received 22 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. DR6 average Analyst price target in the past 3 months is 28.41.
DR6 Financial Forecast
High€0.31
Consensus€0.24
Low€0.16
DR6 Earnings Forecast
Next quarter’s earnings estimate for DR6 is EUR 0.24 with a range of EUR 0.16 to EUR 0.31. The previous quarter’s EPS was EUR 0.28. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€335M
Consensus€328M
Low€321M
DR6 Sales Forecast
Next quarter’s sales forecast for DR6 is EUR 327.58M with a range of EUR 321.35M to EUR 335.15M. The previous quarter’s sales results were EUR 309.41M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
DR6 Stock Forecast FAQ
What is DE:DR6’s average 12-month price target, according to analysts?
Based on analyst ratings, ACADIA Pharmaceuticals’s 12-month average price target is €28.41.
What is DE:DR6’s upside potential, based on the analysts’ average price target?
ACADIA Pharmaceuticals has 74.93% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ACADIA Pharmaceuticals a Buy, Sell or Hold?
ACADIA Pharmaceuticals has a consensus rating of Strong Buy, which is based on 11 buy ratings, 3 hold ratings and 0 sell ratings.
What is ACADIA Pharmaceuticals’s share price target?
The average share price target for ACADIA Pharmaceuticals is €28.41. This is based on 14 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €34.35, and the lowest forecast is €20.79. The average share price target represents a 74.93% increase from the current price of €16.24.
What do analysts say about ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Street analysts.
How can I buy shares of ACADIA Pharmaceuticals?
To buy shares of DE:DR6, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
